United States
Choose your country or region:
France
Germany
Italy
Japan
United Kingdom
About
Leadership
Board of Directors
Company History
Corporate Impact and Community Relations
Health Equity
Our Collaborations
Contact Us
Newsroom
News & Stories
Press Releases
Multimedia
Our Tests
Cologuard®
OncoExTra™
Oncoguard® Liver
Oncotype DX®
Oncotype DX Breast DCIS Score®
Oncotype DX Breast Recurrence Score®
Oncotype DX Colon Recurrence Score®
Riskguard™
Provider
Patient
Pipeline & Data
Breast Radiation Score
Next Generation Cologuard
Colorectal Cancer Blood
LBgard® Blood Tubes
Molecular Residual Disease
Cancerguard™
Our Expertise
Cancerguard™ Science
Multi-Cancer Early Detection Thought Leadership
Clinical Studies
Research
Publications & Abstracts
Exact Academy
Investor Relations
Press Releases
Events & Presentations
Environmental, Social, and Governance (ESG)
Stock Information
Financial Information
Email Alerts
Contact Us
Join Our Team
×
DIGITAL NEWSROOM
Posts by:
Exact Sciences
November 01, 2023
Exact Sciences Announces Third-Quarter 2023 Results
October 22, 2023
Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly outperforming fecal immunochemical testing (FIT) for cancer and precancer detection
October 21, 2023
Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress
October 09, 2023
Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023
September 12, 2023
Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience
August 30, 2023
Exact Sciences Lab and OncoExTra Test Selected by National Cancer Institute for ComboMATCH Clinical TRIALs
August 21, 2023
Not a Wall But an Obstacle Course: New Findings Reveal Why 45-Year-Olds Are Avoiding Colorectal Cancer Screenings
August 01, 2023
Exact Sciences Announces Second-Quarter 2023 Results
June 21, 2023
Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
June 20, 2023
Next Generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent specificity, Raising the Bar in Non-invasive Screening
June 01, 2023
EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK
®
CERTIFICATION
™
May 17, 2023
EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS
1
2
3
4
5
6
7
8
9
...